MaaT Pharma’s PICASSO trial met its primary goal, so why is the melanoma efficacy picture still uncertain?
MaaT Pharma's PICASSO trial met its safety goal but showed similar melanoma responses. Discover what the results mean for MaaT034.
MaaT Pharma's PICASSO trial met its safety goal but showed similar melanoma responses. Discover what the results mean for MaaT034.
Tissium has secured approximately $68 million to expand the U.S. rollout of Coaptium Connect, a light-activated polymer system for peripheral nerve repair. Its commercial opportunity is significant, but surgeon adoption and stronger comparative evidence remain crucial.